Thalidomide for Dermatologic Conditions | Therapeutic Cheat Sheet
Thalidomide was introduced in the 1950s as a “safe” sleeping medication; however, it quickly became vilified and was removed from the market for its severe teratogenic effects, most commonly phecomelia, or loss of arms and legs. Despite these devastating birth defects, thalidomide has a variety of indications for dermatologic conditions, with manageable side effects when used appropriately. We …
Thalidomide was introduced in the 1950s as a “safe” sleeping medication; however, it quickly became vilified and was removed from the market for its severe teratogenic effects, most commonly phecomelia, or loss of arms and legs. Despite these devastating birth defects, thalidomide has a variety of indications for dermatologic conditions, with manageable side effects when used appropriately. We … Continue reading "Thalidomide for Dermatologic Conditions | Therapeutic Cheat Sheet"
Hyperhidrosis affects up to 4.8% of people in the United States, causing significant impacts in patient quality of life.1 Often times, the etiology of symptoms cannot be identified, resulting in a subset of disease termed “primary hyperhidrosis.” Symptoms may be focal or generalized. Because there is a scarcity of FDA-approved treatments for primary hyperhidrosis, treatment often requires a mu … 
Primary hyperhidrosis (PHH) is a dermatologic condition characterized by overactivity of eccrine glands resulting in excessive sweating primarily affecting the palms, soles, axillae, and craniofacial area. PHH is not caused by other conditions, whereas secondary hyperhidrosis is caused by an underlying medical condition or medication side effect. Botulinum toxin injections are often used as second … 
Cutaneous T cell lymphoma (CTCL) is the most common primary cutaneous lymphoma, and in some patients, it could be persistent for decades. Therapy for CTCL depends on disease stage and response to prior treatments. In this month’s installment of Therapeutic Cheat Sheets, we will discuss use of bexarotene for the treatment of CTCL.
BEXAROTENE THERAPEUTIC CHEAT SHEET
Compiled by: Adrianna Gonzale … 
Chronic pruritus affects 8-16% of the general population and has a profound impact on patient quality of life.1-3Although the symptom of pruritus may originate from a number of underlying etiologies, including metabolic derangements and infectious causes, along with neoplastic, inflammatory, or psychiatric conditions, other cases may be idiopathic in nature.4 Given the diversity of underlying cont …